Neurogene NGNE
Neurogene reports $29.02 million net loss for Q3 2026
Neurogene (NGNE) filed a 10-Q with the SEC on Nov 9, 2026, 4:03 pm ET. Source: the filing on SEC EDGAR.
- Form
- 10-Q
- Filed
- Importance
- Notable
- Accession
- 0001404644-26-000069
- Net loss of $29.02 million for the three months ended Sep 30, 2026
- Diluted EPS of -$3.90 for the three months ended Sep 30, 2026
- Cash and equivalents of $78.94 million at Sep 30, 2026
Written from the 10-Q on EDGAR. AI can make mistakes. Check the filing.
What changed since last quarter
2 new risk factors · 2 removed
Compared with the 10-Q for the period ended Jun 30, 2026.
| This filing | Previous | Change vs prior 10-Q | |
|---|---|---|---|
| Operating income and margin | −$32.38M | −$36.67M | +12% |
| Net income | −$29.02M | −$34.49M | +16% |
| Operating cash flow | −$29.15M | −$23.76M | −23% |
| Cash | $78.94M | $112.49M | −30% |
New risk factors (2)
- Security" and "—Other Regulatory Matters" in our Annual Report on Form 10-K for a more detailed description of the laws that may affect our ability to operate.
- We rely and expect to continue to rely upon a combination of patents, trademarks, trade secret protection and confidentiality agreements to protect the intellectual property related to our product candidates and technologies and to prevent third parties from unfairly competing with us. Our success depends in large…
Removed risk factors (2)
- States or abroad, including the United States Patent and Trademark Office ("USPTO"). Further, if we encounter delays in any clinical trials or delays in obtaining regulatory approval, the period of time during which we could market product candidates under patent protection would be reduced. Thus, the patents that we…
- This could have a material adverse effect on our competitive position, business, financial conditions, operations, and prospects.